Our Management Team


Our co-founders Alex Johnson and Emily Crossley met after their sons were diagnosed with Duchenne muscular dystrophy. They both set up charities, Alex with Joining Jack, Emily with the Duchenne Children’s Trust. The two charities have now joined forces to become Duchenne UK.


Emily Crossley

Emily is the co-founder and joint CEO of Duchenne UK. 

Emily set up the Duchenne Children’s Trust in 2012 after her son was diagnosed with Duchenne. Before that she was a reporter and anchor for Channel 4 News and CNN International. The Duchenne Children's Trust raised £3.5million in its first three years, to spend on clinical trials, research, and clinical trial infrastructure. The charity set up the annual Duchenne Dash, which brings in money for research and raises awareness around Duchenne muscular dystrophy. Emily has advocated on behalf of patients around the world. She's spoken many times in the Houses of Parliament. She is a member of the MHRA patient group consultative forum. 


Alex Johnson

Alex is the co-founder and joint CEO of Duchenne UK.

Alex founded the charity Joining Jack with her husband, ex-rugby league player Andy Johnson, following their son Jack’s diagnosis with Duchenne muscular dystrophy in 2011. The rugby community came together to help the family and helped them create international awareness for Duchenne with innovative campaigns like #Link4DMD. The charity has successfully raised more than £2 million to spend on translational research and clinical trials. Alex has subsequently joined the board of United Parent Project (UPPMD) and has helped organise international awareness events like World Duchenne Awareness Day. She has represented the Duchenne community by speaking at international conferences around the world, workshops and meetings with the FDA, EMA, MHRA, NICE and at the Houses of Parliament. Alex was honoured to join the steering committee that helped organise a workshop with the EMA on exon skipping. Following the meeting the steering committee published an article in the Lancet. Alex completed training at a Eurordis summer school to become a trained patient advocate and is also a member of the MHRA patient group consultative forum.


Naomi Litchfield

Naomi is Director of Patient Engagement and Clinical Care for Duchenne UK.

Naomi trained as a paediatric nurse at the John Radcliffe Hospital in Oxford, before joining Great Ormond Street Hospital where she worked as a senior clinical research nurse in the neuromuscular team. After GOSH, she gained industry experience working at Clinigen and Biomarin. 


David Bull

Dr David Bull is Director of Research for Duchenne UK. David spent 16 years as a research scientist at GlaxoSmithKline. His initial training was in neuroscience, studying novel treatments for Parkinson’s Disease and Schizophrenia, David then led the research team looking into the molecular biology of 5-HT receptors in terms of treating migraine.

David then moved into science development in the UK and USA and led the UK Learning & Development team, subsequently becoming VP Leadership & Organisation Development for GSK International.